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Abstract
The advent of extended half-life (EHL) recombinant clotting factors and innovative 
non-factor replacement therapeutics, such as emicizumab, offers several advantages 
over existing products for the prophylactic treatment of people living with hemo-
philia (PwH). These include low annual bleeding rates with less frequent dosing, 
higher trough plasma concentrations, and a more convenient route of administration. 
However, increasing use of these therapies poses challenges to clinicians and coagu-
lation laboratories due to the lack of standardized assays for monitoring of hemostatic 
parameters, and the potential for misinterpretation of test results, which may jeop-
ardize patient safety. Definitive diagnosis of hemophilia and treatment monitoring is 
reliant on demonstrating factor VIII (FVIII; hemophilia A) or factor IX (FIX; hemophilia 
B) deficiency using a functional coagulation assay. The most frequently used assays 
are based on activated partial thromboplastin time, using a one-stage or two-stage 
process. While one-stage and chromogenic assays have performed well with human-
derived FVIII and FIX and full-length recombinant products, EHL recombinant factors 
are heterogeneous in structure and mode of action and therefore show wide varia-
tion in activity levels between different one-stage assays, and between one-stage 
and chromogenic assays. In the context of the recommended stepwise approach for 
laboratory diagnosis of hemophilia, we examine the diagnostic challenges associated 
with the use of EHL factors and novel non-factor therapeutics and consider the op-
timal diagnostic approach in PwH who are receiving these treatments. Ultimately, 
accurate diagnostic solutions are a prerequisite for personalized therapy to minimize 
treatment burden and improve quality of life in PwH.
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1  | BACKGROUND
Hemophilia results from a deficiency of coagulation factor VIII 
(FVIII; hemophilia A) or factor IX (FIX; hemophilia B). Accurate 
diagnosis of hemophilia is essential to inform appropriate man-
agement of people living with hemophilia (PwH) and can only be 
made with the support of a comprehensive laboratory service.1-4 
As highlighted in World Federation of Hemophilia guidelines, cor-
rect diagnosis is dependent on laboratories following strict proto-
cols and procedures, which requires knowledge and expertise in 
coagulation laboratory testing, use of the correct equipment and 
reagents, and quality assurance.1
Effective management of hemophilia involves preventing and 
treating bleeding episodes by administering the deficient clotting fac-
tor or using new treatment approaches such as emicizumab (for he-
mophilia A), preferably in a comprehensive care setting.1 The current 
cornerstone of management is factor replacement therapy,1,3 which 
is associated with potential infusion-related side effects, including 
pyrexia, headache, and immunologic reactions. Of particular impor-
tance is the development of neutralizing anti-FVIII antibodies (inhibi-
tors) that significantly reduce the effectiveness of FVIII treatment and 
complicate the therapeutic management of patients. Thus, accurate 
and precise clotting factor assays and inhibitor testing are essential 
for optimal management of hemophilia. Guidelines also recommend 
that laboratory specialists should work alongside the medical director, 
nurse coordinator, musculoskeletal expert, and psychosocial expert to 
form a multidisciplinary core team responsible for delivering compre-
hensive care for PwH.1
Accurate tailoring of therapy for PwH also requires regular labo-
ratory follow-up to determine specific trough and peak levels of re-
placement factors for each individual.5,6 Early studies found that joint 
disease in PwH can be minimized through a prophylactic treatment 
approach by preventing FVIII or FIX concentrations from falling below 
1% (ie, the detection limit),7 indicating that the incidence of joint 
bleeds is associated with trough levels of administered therapeutics. 
The probability of spontaneous joint bleeds decreases with an increase 
of FVIII activity.5,6 Given that as few as three consecutive joint bleeds 
can expose joints to irreversible harm,8 modern factor replacement 
therapy aims to achieve a zero-bleeds strategy. More recent work has 
highlighted significant individual variation in the pharmacokinetics of 
replacement factor concentrates, providing further rationale for phar-
macokinetic-based personalized prophylactic therapy.9,10 Modern re-
gimes take bleeding pattern, condition of the musculoskeletal system, 
level and timing of physical activity, and blood coagulation factor lev-
els into account;11 considering these aspects some patients may need 
to achieve higher trough levels (ie, exceeding 1%-3%).
In pursuit of the goal of tailored therapy, electronic apps are 
increasingly being used by patients to track bleeds and factor lev-
els, and a newer generation of extended half-life (EHL) factor prod-
ucts have been developed (Table 1), offering several advantages 
over standard products, including a lower frequency of dosing and 
higher trough plasma concentrations.3,12 However, the availability 
of EHL factors raises new issues of accuracy and reproducibility for 
laboratory testing, centered around the ability of laboratories to 
achieve comparable activity measurements for post-infusion sam-
ples.13 A number of non-factor replacement molecules have also 
been developed, such as emicizumab, which is approved for prophy-
laxis of hemorrhage in patients with hemophilia A with or without 
FVIII inhibitors in numerous countries worldwide, including Europe, 
the United States, Japan, and Australia.14,15 Laboratory monitoring 
of coagulation status during emicizumab therapy can help to rule out 
anti-drug antibodies (ADAs) in the event of breakthrough sponta-
neous bleeding, as part of a pre-operative assessment to determine 
adequacy of hemostasis for surgical procedures, or in cases in which 
co-administration of factor concentrates is necessary. However, 
as the mechanism of action of emicizumab differs from FVIII this 
has implications for the selection of diagnostic assay and interpre-
tation of laboratory results, whereby product-specific calibration is 
required to enable therapeutic drug monitoring. Additionally, labo-
ratory monitoring with differential application of specific FVIII sin-
gle-factor assays can discriminate endogenous FVIII activity from 
that associated with FVIII replacement products and emicizumab.
Other novel therapeutic approaches may also present challenges 
for clinical laboratories. Non-factor replacement molecules fitusiran and 
concizumab do not target the intrinsic tenase complex and are being de-
veloped specifically for the treatment of both hemophilia A and B; these 
agents are currently being investigated in phase II/III trials,16-19 in which 
their net effect on the restoration of hemostasis is demonstrated by an 
indirect or direct dose-dependent increase in thrombin generation.16-17,20 
Advances in gene therapy also offer hope to PwH,21,22 but may necessi-
tate long-term monitoring of factor levels to confirm continued efficacy. 
Ultimately, while the development of innovative coagulant agents has 
the potential to reduce treatment burden and increase the quality of life 
for PwH, methods for precise monitoring of hemostatic parameters with 
these products/approaches need to evolve in parallel.20,23,24
In summary, the realization of personalized treatment regimens 
with EHL factor preparations and novel therapeutics such as emici-
zumab requires the availability of precision diagnostic approaches 
for accurate measurement of these agents. In this review, we aim 
to provide education around the optimal diagnostic and therapeutic 
monitoring approach in PwH who are receiving treatment with EHL 
factors or emicizumab.
2  | DIAGNOSTIC PATHWAYS IN 
HEMOPHILIA
2.1 | Screening tests
Current guidelines recommend a stepwise approach in patients 
presenting with symptoms consistent with spontaneous bleeding 
(Figure 1). Initial screening tests to identify the cause of bleeding 
include the activated clotting time (aCT) and activated partial throm-
boplastin time (aPTT) tests.1
aCT is a point-of-care test whereby blood samples are collected 
per standard guidelines,1,25 and immediately added to a surface 
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activator (eg, kaolin); the time to clot formation is known as the aCT 
and is sensitive to deficiencies in factors VIII (<25% of normal), IX, X, 
XI, and XII. aCT is mostly used for anticoagulation monitoring, being 
sensitive to parenteral and oral anticoagulants (Xa/IIa antagonists); 
a limitation is that the test is sensitive to platelet count and hemo-
dilution.26 Due to low sensitivity and specificity, aCT is not recom-
mended for diagnosis and monitoring of hemophilia patients under 
elective conditions.
aPTT is a standard laboratory test and is more precise than aCT. 
Evaluation of aPTT involves incubation of platelet poor plasma (PPP) 
with a phospholipid reagent and subsequent addition of a surface 
activator; the same process is performed in parallel using control 
plasma.27 A prolonged aPTT in the presence of a normal prothrombin 
time and platelet count is suggestive of hemophilia.1 However, sev-
eral variables can affect the measurement of aPTT (Figure 2), which 
is also prolonged by any deficiency of the intrinsic (contact) pathway 
(eg, deficiencies of factors XII, XI, and IX) and common coagulation 
pathway (eg, deficiencies of factors V, X, II, or fibrinogen) and in the 
presence of inhibitors. Measurement techniques may also influence 
aPTT; for example, reagents with different sensitivities are available, 
and deviation from manufacturer recommended incubation times or 
the use of different coagulometers can affect clotting times.27,28
Subsequent correction or inhibition on mixing studies using pooled 
normal plasma can help to determine whether the prolonged aPTT is 
due to coagulation factor deficiency or inhibitors (eg, circulating lupus 
anticoagulants, or specific coagulation factor inhibitors), respectively. 
Mixing studies with FVIII- or FIX-deficient plasma can be used to dis-
tinguish between hemophilia A/B if a factor assay is not available.1
2.2 | Confirmation tests
Definitive diagnosis of hemophilia and monitoring of treatment 
depends on demonstration of FVIII or FIX deficiency by functional 
coagulation assay (FVIII:C or FIX:C) and exclusion of differential 
diagnoses such as von Willebrand disease.1-4 Coagulation assays 
F I G U R E  1   Stepwise approach for laboratory testing of blood and plasma samples in patients presenting with bleeding symptoms.  
aCT, activated clotting time; aPTT, activated partial thromboplastin time; POCT, point-of-care test
Specificity of the assay increases with
declining fraction of patient plasma
Single factor:
clotting
Global assay:
aPTT
Single factor:
chromogenic
Whole blood:
aCT
Plasma
ReagentWhole blood
Activator
Plasma
Deficient 
plasma
Reagent
Plasma
Reagent
F I G U R E  2   Variables affecting measurement of aPTT.  
aPTT, activated partial thromboplastin time
Measurement
technique
Calibrator
Activator Phospholipid
source
Factor-deficient
plasma
aPTT-based
assay
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can be used to determine the severity of hemophilia, to check co-
agulation status prior to surgery, and for dose optimization during 
prophylactic treatment in which a decrease in factor activity during 
adequate treatment may indicate inhibitor development.
One-stage assays based on aPTT are the most commonly used 
functional coagulation assays and are widely available in clinical 
laboratories.1,4,27 The assay compares the ability of platelet-poor 
citrated test plasma (ie, patient sample) and standard plasma to 
correct the aPTT of a plasma that is totally deficient in FVIII or FIX 
but contains all other components of the normal clotting process.27 
Samples are pre-diluted with assay buffer before addition of aPTT 
reagent, comprising phospholipid plus contact activator, and sample 
FVIII or FIX activity determines coagulation time. Samples may also 
be pre-diluted with FVIII- or FIX-deficient plasma to construct low 
curves when very low levels are measured. Assay performance is 
affected by the type of contact activator (that varies with each aPTT 
reagent), factor-deficient plasma, and the instrument on which the 
assay is performed. Different aPTT reagents have varying sensitivi-
ties to coagulation factor deficiencies, detection of lupus anticoagu-
lants, and heparin sensitivities. The large majority of aPTT reagents 
will be abnormal in moderate and severe hemophilia; however, not 
all reagents will detect mild hemophilia. Thus, for diagnosing hemo-
philia it is important to select an aPTT reagent with proven capacity 
to detect all hemophilia categories (ie, mild to severe hemophilia).4 In 
addition, it is important for each performing laboratory to know the 
sensitivity of their reagent to detection of FVIII and FIX deficiency 
on their respective instruments.
A prolonged aPTT that is not fully corrected into the laborato-
ry-established reference range by mixing patient plasma with an 
equal volume of normal plasma suggests the presence of an inhibi-
tor, such as lupus anticoagulant or neutralizing anti-FVIII or anti-FIX 
antibodies. Confirmation that an inhibitor is directed against a clot-
ting factor requires a specific inhibitor assay.1 The Bethesda assay 
compares activity in a mix of normal plasma and patient plasma with 
heat inactivation of FVIII or FIX activity versus a mix of control and 
normal plasma to determine the percentage of FVIII/FIX activity in-
hibited by a patient's plasma.29 The Nijmegen modification of the 
Bethesda assay increases sensitivity.30,31 One Bethesda unit (BU) is 
defined as the amount of an inhibitor that will neutralize half of 1 
unit of FVIII:C in normal plasma after a 2-hour incubation at 37°C, 
and an inhibitor titer of ≥0.6 BU/mL (or ≥0.5 BU/mL following heat 
treatment) should be considered clinically relevant.1 The Bethesda 
assay might be performed in several clinical scenarios, including in 
previously untreated patients to confirm reduced recovery after fac-
tor administration, for prognostic considerations (ie, determination 
of high or low responders) and therapeutic monitoring of immune 
tolerance induction, and for surveillance when switching factors or 
switching from factor- to non-factor-based regimens (particularly 
after intermittent application of FVIII).
Limitations of one-stage assays include susceptibility to inter-
ference from pre-analytical sample handling and processing (eg, 
pre-activation of FVIII), anti-phospholipid antibodies, or heparin 
contamination, and the potential for misleading results.32,33 For 
example, in individuals with mild hemophilia A and genetic mutations 
of FVIII, FVIII:C measured by a one-stage assay may be higher than 
when measured using a two-stage aPTT-based assay (which is rarely 
used or available in clinical laboratories) or chromogenic substrate 
assay (CSA; which is also based on the two-stage procedure) and 
may appear normal; the reverse is also possible.33
The CSA is a two-stage assay based on the principle that the 
amount of FVIII is rate-limiting during clotting of a test mixture con-
taining FX in excess, activated FIX (FIXa), phospholipid, and calcium 
ions.27,34 PPP is incubated with the reagent cocktail at 37°C and 
thrombin. Color formation is directly proportional to FVIII:C or FIX:C 
activity in the PPP sample and can be measured spectrophotomet-
rically.27 FX in the reagent can be of human or bovine origin, which 
has implications for the assessment of coagulation status during 
emicizumab therapy (as discussed in more detail below). CSAs are 
generally more sensitive to mildly lowered factor activity and are 
more specific than one-stage assays due to the high dilution factor 
of the sample,4,32 although for some FVIII mutations chromogenic 
and one-stage assays can complement each other.35 While chromo-
genic assay kits are commercially available, they are not uniformly 
approved by regulatory agencies such as the US Food and Drug 
Administration (FDA).
A chromogenic version of the Bethesda assay has proven suc-
cessful in testing for the presence of inhibitors,36 and can determine 
FVIII inhibitor titer in the presence of emicizumab, as discussed 
below.37
3  | EFFEC TS OF E X TENDED HALF-
LIFE FAC TORS OR EMICIZUMAB ON 
DIAGNOSTIC PERFORMANCE OF FAC TOR 
A SSAYS
3.1 | Influence of extended half-life factors on 
commonly used laboratory tests for hemophilia
Three key molecular strategies have been used to extend the half-
lives of recombinant FVIII (rFVIII) and recombinant FIX (rFIX) prepa-
rations: attachment of polyethylene glycol (PEG; PEGylation); fusion 
to other proteins such as recombinant human albumin or the frag-
ment crystallizable (Fc) region of human immunoglobulin G1 (IgG1); 
and development of a single-chain protein (Table 1).12 PEG conju-
gation increases the circulation time of FVIII and FIX by protecting 
against enzymatic degradation; similarly, fusion to the Fc-part of IgG 
or to albumin protects FVIII and FIX from lysosomal sorting and deg-
radation.39 While most commercially available FVIII concentrates 
consist of two chains, the rFVIII single-chain (rFVIII-SC) preparation 
comprises a truncated B-domain that covalently links the heavy and 
light chains to improve the pharmacokinetic properties of the mol-
ecule.39 The half-lives of EHL-rFIX products can be extended four- 
to six-fold using these technologies, while the half-life extension of 
EHL-rFVIII products is restricted to 1.5- to two-fold due to their in-
teraction with von Willebrand factor.39
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A number of PEGylated FVIII and FIX products have been inves-
tigated in hemophilia clinical trials, or are currently in development. 
Rurioctocog alfa pegol (BAX-855; Adynovate®), a PEGylated form 
of full-length rFVIII, is licensed for the prevention and treatment of 
hemorrhage in hemophilia A40; nonacog beta pegol (N9-GP; Refixia®), 
a PEGylated version of the FIX activation peptide, is approved for 
the prevention and treatment of hemorrhage in adult hemophilia 
B41; and turoctocog alfa pegol (N8-GP; Esperoct®), which contains 
a truncated B-domain attached to a PEG molecule, is approved 
for treatment and prophylaxis of bleeding in patients 12 years and 
above with hemophilia A.42 Damoctocog alfa pegol (BAY94-9027), a 
PEGylated form of B-domain-depleted rFVIII molecule, is undergoing 
clinical assessment.13,39 In terms of fusion proteins, eftrenonacog 
alfa (rFIX-Fc; Alprolix®), a single recombinant FIX molecule fused to 
the Fc domain of IgG1, was the first EHL factor concentrate to gain 
FDA approval for the prophylaxis and treatment of hemophilia B43; 
albutrepenonacog alfa (rFIX-FP; Idelvion®), a fusion protein between 
rFIX and human albumin, was subsequently approved in this indica-
tion.39,44 Lonoctocog alfa (rFVIII-SC; Afstyla®) is approved for the 
treatment of hemophilia A across a number of countries.45
Although one-stage and chromogenic assays have both per-
formed well with human-derived FVIII and FIX and full-length re-
combinant products, EHL recombinant factors show wide variation 
in activity levels between different one-stage assays, and between 
one-stage and chromogenic assays.24,46 In one-stage assays, these 
differences relate to the type of contact activator used, which is ei-
ther silica, ellagic acid, kaolin, or polyphenolic acid.38,47 Therefore, 
for some EHL-rFVIII and EHL-rFIX products, certain one-stage as-
says are unsuitable for monitoring purposes.38,47
The International Prophylaxis Study Group (IPSG) recently pro-
duced a summary of one-stage assay results according to EHL con-
centrate and aPTT reagent, based on laboratory and clinical studies 
(Table 2). Of note, not all of the study designs were the same; some 
were field studies and others were limited to a single, or only a few, 
reference laboratories.38,47 Looking at rFVIII concentrates, only 
rFVIII-Fc and rFVIII-PEG appeared to have no serious issues with 
any tested reagent, although this conclusion was based on findings 
from field studies only.48 BAY94-9027 and N8-GP showed discrep-
ant findings with respect to silica-based aPTT reagents: correct mea-
surements were achieved with SynthASil® and Pathromtin® SL, but 
decreased recovery was observed with STA®-PTT Automate and 
PTT-SP and TriniCLOT™. The same was true for ellagic acid reagents, 
with correct measurements achieved with Actin® FS, Actin® FSL, 
and DG Synth, but decreased recovery observed with SynthaFax® 
(N8-GP only).49-53 With regard to the FVIII-SC molecule, all aPTT re-
agents led to decreased recoveries.54,55 Contrary to FDA guidance, 
IPSG and other groups suggest that when assessing FVIII-SC effects, 
it may not be appropriate to multiply the one-stage assay result by a 
factor of two; if chromogenic FVIII assays are available they should 
be preferably used.13,49,56
The measurement of rFIX concentrates with one-stage assays 
has been reported by the IPSG. Both rFIX-Fc and rFIX-FP were cor-
rectly measured using the selection of silica reagents tested, but both 
products resulted in decreased recoveries with kaolin reagents.57,58 
By contrast, N9-GP resulted in approximately four-fold overestima-
tion of FIX levels when certain silica reagents were used,59,60 and 
other reagents underestimated the effects of N9-GP (Actin FS, 
SyntaSIL, and STA®-CK Prest®).61 N9-GP can be correctly measured 
using a polyphenolic acid reagent (CephaScreen) and one ellagic acid 
reagent (SynthaFax)62 (Table 2). Use of product-specific reference 
standards can reduce overestimation of BAX-855 recovery.63
Chromogenic FVIII assays can be used to measure the recover-
ies of all EHL-rFVIII concentrates38,48,53,63-65 (Table 3), as they are 
associated with less variation than one-stage assays and measure-
ments are more precise. However, data relating to the accuracy of 
chromogenic assays for measuring EHL FVIII agents are relatively 
limited and are often based on field studies. Furthermore, the ac-
curate recovery of target analytes by chromogenic FVIII assays may 
be dependent on the use of product-specific references,63 and an 
overestimation of N8-GP recovery has been reported with some 
assays.49,53,64 Data for the two available rFIX chromogenic assays 
(Biophen™ Chromogen factor IX; Rox FIX) are relatively limited: 
N9-GP can be correctly measured using either of these assays59; 
rFIX-Fc can be correctly measured using the BioPhen assay57; 
rFIX-FP can be correctly measured using the Rox assay66 (Table 3).
In addition to interference of coagulation activity tests, the pres-
ence of EHL-FVIII and EHL-FIX agents can make detection of low-ti-
ter FVIII and FIX inhibitors difficult using the Nijmegen Bethesda 
assay.34 It is well established that heat activation and centrifugation 
can be used to eliminate interference from endogenous and ther-
apeutic FVIII, and facilitate low-level inhibitor detection;34 how-
ever, until recently the effectiveness of this pre-analytical protocol 
in samples containing EHL-FVIII and EHL-FIX agents had not been 
investigated. Two small studies have now demonstrated that mo-
lecular modification of FVIII and FIX does not impact heat inactiva-
tion.67,68 The first study demonstrated that a 30-minute incubation 
at 56 resulted in heat inactivation of EHL-FVIII and allowed accurate 
determination of FVIII inhibitors using either one-stage or chromo-
genic assays.67 This finding was confirmed in the subsequent study, 
which also showed that pre-analytic heat treatment can remove in-
terference by EHL-FIX agents.68 Collectively, these findings mean 
that patients do not need to undergo a washout period prior to in-
hibitor measurement.
3.2 | Guidelines for laboratories for monitoring the 
use of extended half-life factors
Guidance on the use of EHL coagulation factor concentrates in 
routine clinical practice was published in 2016 by the United 
Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO).13 
Recommendations to laboratories for monitoring EHL factor con-
centrates included using an assay that has been validated for use 
with the specific EHL factor. This may be a chromogenic assay, a 
one-stage assay with a method shown to give appropriate results, or 
a one-stage assay with an appropriate high-quality product-specific 
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standard (if available). Laboratories should not use an assay known 
to give discrepant values and multiply the result by a correction fac-
tor.13 Recommendations from the Zürich Haemophilia Forum also 
suggested that use of a product-specific standard might be advanta-
geous when monitoring EHL factor concentrates.3,12 Chromogenic 
assays are an appropriate method for measuring EHL-FVIII and 
TA B L E  4   Manufacturer recommendations for laboratory monitoring of approved EHL products
Disease
Molecule 
name
Brand/generic 
name SPC recommendations for laboratory monitoring
Hemophilia A rFVIII-Fc Eloctate®/
Elocta67
• When using an in vitro aPTT-based one-stage clotting assay for determining FVIII activity 
in patients’ blood samples, plasma FVIII activity results can be significantly affected by both 
the type of the aPTT reagent and the reference standard used in the assay.
BAX-855 Adynovate®/
Adynovi40
• A field study has indicated that plasma factor VIII levels can be monitored using either 
a chromogenic substrate assay or a one-stage clotting assay routinely used in clinical 
laboratories.
rFVIII-SC Afstyla®45 • When using an in vitro aPTT-based one-stage clotting assay for determining FVIII 
activity in patients’ blood samples, plasma FVIII activity results can be significantly 
affected by both the type of aPTT reagent and the reference standard used in the assay.
• Also there can be significant discrepancies between assay results obtained by aPTT-
based one-stage clotting assay and the chromogenic assay according to Ph. Eur.
• Plasma FVIII activity in patients receiving Afstyla using either the chromogenic assay or 
the one-stage clotting assay should be monitored to guide the dose administered and 
the frequency of repeat injections.
• The chromogenic assay result most accurately reflects the clinical hemostatic potential 
of Afstyla and is preferred.
• The one-stage clotting assay result underestimates the FVIII activity level compared to 
the chromogenic assay result by approximately 45%.
• If the one-stage clotting assay is used, multiply the result by a conversion factor of 2 to 
determine the patient's FVIII activity level.
N8-GP Esperoct®42 
(Turoctocog alfa 
pegol)
• The FVIII activity of Esperoct can be measured using the conventional FVIII assays, the 
chromogenic assay, and the one-stage assay.
• When using an in vitro aPTT-based one-stage clotting assay for determining FVIII 
activity in patients’ blood samples, plasma FVIII activity results can be significantly 
affected by both the type of aPTT reagent and the reference standard used in the assay.
• When using a one-stage clotting assay some silica-based reagents should be avoided as 
they cause underestimation.
• There can be significant discrepancies between assay results obtained by aPTT-based 
one-stage clotting assay and the chromogenic assay according to Ph. Eur.
Hemophilia B rFIX-Fc Alprolix®43 • When using an in vitro aPTT-based one-stage clotting assay for determining FIX activity 
in patients’ blood samples, plasma FIX activity results can be significantly affected by 
both the type of aPTT reagent and the reference standard used in the assay.
• Measurements with a one-stage clotting assay utilizing a kaolin-based aPTT reagent will 
likely result in an underestimation of activity level.
rFIX-FP 
(CSL654)
Idelvion®44 • When using an in vitro aPTT-based one-stage clotting assay for determining FIX activity 
in patients’ blood samples, plasma FIX activity results can be significantly affected by 
both the type of aPTT reagent and the reference standard used in the assay.
• Measurement with a one-stage clotting assay using a kaolin-based aPTT reagent or Actin 
FS aPTT reagent will likely result in an underestimation of activity level.
N9-GP Refixia®41/
Rebinyn®
• Due to the interference of polyethylene glycol (PEG) in the one-stage clotting assay with 
various aPTT reagents, it is recommended to use a chromogenic assay (eg, Rox Factor IX 
or Biophen) when monitoring is needed.
• If a chromogenic assay is not available, it is recommended to use a one-stage clotting 
assay with an aPTT reagent (eg, Cephascreen) qualified for use with Refixia.
• For modified long-acting factor products it is known that the one-stage clotting assay 
results are highly dependent on the aPTT reagent and reference standard used.
• For Refixia some reagents will cause underestimation (30-50%), while most silica-
containing reagents will cause severe overestimation of the factor IX activity (more than 
400%). Therefore, silica-based reagents should be avoided.
• Use of a reference laboratory is recommended when a chromogenic assay or a qualified 
one-stage clotting assay is not available locally.
Abbreviations: aPTT, activated partial thromboplastin time; EHL, extended half-life product; Fc, fragment crystallizable; FIX, factor IX; FVIII, factor 
VIII; Ph. Eur., European Pharmacopoeia; rFIX, recombinant factor IX; rFVIII, recombinant factor VIII; SC, single chain; SPC, summary of product 
characteristics.
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EHL-FIX concentrates, but performance of one-stage assays de-
pends on the reagent used38,47 and it would likely be impractical, 
and costly, for laboratories to offer multiple one-stage assays (ie, 
with different reagents). Of note, manufacturers are required to in-
clude recommendations for suitable test kits for laboratory monitor-
ing of their EHL products in the summary of product characteristics 
(Table 4).40-45,69
3.3 | Influence of emicizumab on commonly used 
tests for hemophilia A
Emicizumab (Hemlibra®) is a chimeric bispecific monoclonal anti-
body that binds to both FIXa and FX, mediating the activation of 
FX to replace missing FVIIIa. The antibody is approved in several 
countries worldwide, including Europe, the United States, Japan, and 
Australia for prophylaxis of hemorrhage in patients with hemophilia 
A with or without FVIII inhibitors.14,15 Emicizumab is not neutralized 
by anti-FVIII antibodies (ie, inhibitors)70 and has a plasma half-life of 
4 to 5 weeks, permitting subcutaneous administration once weekly 
or once every 2 or 4 weeks.71
Unlike FVIII, emicizumab does not require activation for cofactor 
activity and this has implications for the accuracy of one-stage FVIII 
assays and thus the selection of diagnostic assay, their modification, 
and interpretation of results (Table 5).72 Emicizumab and FVIII dif-
fer significantly in terms of affinity, regulation, and FIXa-enhancing 
activity, with the activity of emicizumab depending predominantly 
on the amount of FIXa generated.15,73 Given that the amount of 
FIXa present in one-stage and two-stage chromogenic assays differs 
substantially and, moreover, due to the time-dependent difference 
between non-modified aPTT and chromogenic assays, the activity 
of emicizumab varies greatly between different diagnostic assays. 
Furthermore, as the molecule has a 4- to 5-week half-life, emici-
zumab may affect laboratory tests for up to 6 months after dosing.
FVIII activation is the rate-determining step of the global aPTT 
assay, and emicizumab does not require activation; therefore, patients 
treated with emicizumab will have a normal aPTT test result regardless 
of the aPTT reagent used, even at sub-therapeutic emicizumab plasma 
concentrations of 2-5 µg.74 Normal-range aPTT results for patients re-
ceiving emicizumab therapy are thus misrepresentative of true coag-
ulation status.75 Therefore, the standard one-stage aPTT-based FVIII 
assay must not be used in the presence of emicizumab, as it leads to 
substantial overestimation of hemostatic activity.76,77 Studies exploring 
the effect of emicizumab on various coagulation laboratory tests also 
found a strong effect of emicizumab on several other aPTT-based assays 
including Protein C activity, Protein S activity, and activated Protein C 
ratio.76,77 Therefore, the aim of hemostatic monitoring in patients re-
ceiving emicizumab is to determine emicizumab plasma concentration.
A modified one-stage FVIII clotting assay can be used to mea-
sure plasma emicizumab concentrations.74,79 The assay is calibrated 
against emicizumab using a dedicated plasma emicizumab cali-
brator and two levels of control,79 which are commercially avail-
able (r2 Diagnostics; Haemochrom Diagnostica) for use on various 
diagnostic platforms. Notably, the assay uses a higher sample dilu-
tion compared with the one-stage FVIII assay (1:8 sample predilu-
tion by the analyzer), enabling measurement of a dynamic range of 
emicizumab (10-100 µg) in the original plasma sample. Emicizumab 
concentrations determined with the modified one-stage assay (OSA) 
have been shown to correlate significantly with those determined 
by a non-commercial enzyme-linked immunosorbent assay (ELISA) 
method previously used in the HAVEN studies.74 In a more recent 
analysis the modified OSA demonstrated good analytical perfor-
mance for measuring emicizumab on cobas t 511/711 analyzers.80
Chromogenic FVIII assays are only sensitive to emicizumab if they 
use human-derived factors because emicizumab drives coagulation 
with human FIXa and FX, but not bovine FIXa and FX.75 Therefore, 
chromogenic FVIII testing using human FIXa and FX can be used for 
the quantitative detection of in vitro emicizumab if calibration is done 
versus emicizumab.77,81 Clinical studies are under way to determine 
whether CSA-reported FVIII activity is sufficiently equivalent to emi-
cizumab levels to permit clinical utility. Measurement of emicizumab in 
the sample may also be influenced by FVIII sample content, although 
pre-analytical heat treatment may potentially reduce this effect.
aPTT-based clotting assays determining FVIII activity or chromo-
genic FX activation assays do not reflect the combined effect of emi-
cizumab and additional anti-hemophilic agents such as recombinant 
FVIII or bypassing agents such as recombinant factor VIIa (rFVIIa) or 
activated prothrombin complex concentrates (aPCC). FVIII activity 
in the presence of emicizumab can be exclusively determined using 
TA B L E  5   Interpretation of unexpected assay results in 
emicizumab-treated patients72
Assay Result for patient on emicizumab
aPTT Overactive—normalizes at very low 
concentrations of emicizumab
FVIII one-stage activity 
assay (aPTT-based)
Overactive—normalizes at very low 
concentrations of emicizumab
Modified FVIII one-
stage assay
Sensitive to emicizumab—can be used 
to determine emicizumab plasma 
concentration
FVIII chromogenic 
activity assay (bovine 
components)
Insensitive to emicizumab (emicizumab 
does not accelerate FXa formation by 
bovine FIXa) —can be used to measure 
endogenous and infused FVIII levels
FVIII chromogenic 
activity assay (human 
components)
Sensitive to emicizumab—emicizumab 
and FVIIIa co-factor properties are not 
identical. FVIII:C is an approximation of 
emicizumab hemostatic activity
All Bethesda assays 
using one-stage FVIII 
methods
False negative—emicizumab drives 
coagulation via human FIX and FX in 
human plasma, regardless of presence 
of inhibitors to FVIII
Chromogenic Bethesda 
assay36
Unaffected by emicizumab—assay uses 
a bovine protein-based chromogenic 
assay, which is not affected by 
emicizumab
Abbreviations: aPTT, activated partial thromboplastin time; F, factor.
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a chromogenic FVIII assay based on bovine factors, thus permitting 
measurement of endogenous or infused FVIII activity independent 
of emicizumab.75 Importantly, aPCC and rFVIIa should be discontin-
ued the day before starting emicizumab treatment.14 Use of aPCC 
(that contains major substrates of emicizumab82) should be avoided 
in patients receiving emicizumab prophylaxis unless no other treat-
ment options/alternatives are available; if aPCC is indicated, the ini-
tial dose should not exceed 50 U/kg and laboratory monitoring for 
the diagnosis of thrombotic microangiopathy is recommended.14
Emicizumab causes false-negative results with the Bethesda 
assay.37 This assay employs heat inactivation to destroy residual 
FVIII activity and as emicizumab is not inactivated by heat or an-
ti-FVIII antibodies, no inhibition is detected as emicizumab restores 
clotting. In contrast, chromogenic Bethesda assays that use bovine 
components are not affected by emicizumab and can be used to 
measure inhibitor titer; these assays have recently been developed 
and are commercially available.36-37,78 Researchers are also looking 
at ways to modify existing assays (ie, clot waveform analysis for 
evaluating FVIII activity in the presence of emicizumab) or to de-
velop novel methods of restoring the utility of the classic Bethesda 
assay (ie, development of anti-idiotype antibodies to neutralize emi-
cizumab interference).83,84
Although emicizumab is expected to exhibit a lower immunoge-
nicity than FVIII,85 the development of ADAs was reported in a small 
proportion of individuals during the HAVEN clinical development 
program, as detected by ELISA.86 No commercial assay for direct 
identification of emicizumab ADAs is currently available. However, 
functional assays such as aPTT or the modified FVIII OSA can po-
tentially be used to indirectly detect the possible presence of ADAs 
when suspected to be the cause of increased bleeding.
3.4 | Guidelines for laboratories for monitoring the 
use of emicizumab
There are no published recommendations regarding hemostatic 
monitoring during treatment with emicizumab. Table 5 summarizes 
current evidence on the interpretation of laboratory results in emi-
cizumab-treated patients.14,15 FVIII chromogenic assays using hu-
man-derived components are suitable for detection of emicizumab 
hemostatic activity in heat-treated plasma quantitative samples.81 
However, due to mechanistic differences between emicizumab and 
FVIII, the aim of hemostatic monitoring in emicizumab-treated pa-
tients is to determine emicizumab plasma concentrations. A modi-
fied FVIII OSA provides an accurate method for the quantitative 
determination of plasma emicizumab concentration.80 FVIII chro-
mogenic assays that use bovine-based components can be used to 
measure endogenous and infused FVIII levels in the presence of emi-
cizumab.75 For measurement of FVIII inhibitor titer in the presence 
of emicizumab, a bovine plasma-based chromogenic Bethesda assay 
is suitable.78 Finally, functional assays such as aPTT or the modified 
FVIII OSA can potentially be used to indirectly detect the presence 
of ADAs when suspected to be the cause of increased bleeding.
3.5 | Guidelines for clinicians for the use of EHL 
factor replacement and emicizumab
In the absence of standardized laboratory diagnostics clinical guide-
lines, or where uncertainty exists, a prudent clinical approach may 
be to initiate treatment with EHL factors or emicizumab using the 
standard dosing regimen (according to manufacturer's recommen-
dations) to achieve low annualized bleed rates (ie, zero spontaneous 
bleeds) and then to de-escalate the dose or interval independently 
of laboratory results. Further investigation and standardization may 
help to establish chromogenic FVIII assays that are applicable to all 
EHL factors. Clinicians should also consider tailoring their EHL factor 
portfolio according to the available laboratory tests.
4  | CONCLUSIONS
The advent of EHL factors and emicizumab offers several advan-
tages for the prophylactic treatment of PwH, most notably reduced 
treatment burden, improved patient outcomes, and treatment in 
the presence of FVIII inhibitors. However, the use of these agents 
also presents challenges in terms of patient monitoring, and existing 
guidelines should be updated to reflect the correct diagnostic ap-
proaches in PwH receiving these therapies. Currently, laboratories 
should select a chromogenic or appropriate one-stage assay that 
has been validated for use with the specific treatment. The stand-
ard one-stage aPTT-based FVIII assay cannot be used to measure 
hemostatic activity in the presence of emicizumab, as it leads to 
substantial overestimation of results. A modified one-stage FVIII 
assay provides an accurate method to monitor emicizumab in the 
plasma. Chromogenic FVIII testing using human FIXa and FX can 
quantitatively estimate in vitro emicizumab, while a bovine-based 
chromogenic Bethesda assay can measure inhibitor titer in the pres-
ence of emicizumab. Ultimately, increased awareness of appropriate 
diagnostic approaches will help to optimize patient outcomes and is 
an essential prerequisite to personalized therapy for PwH.
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